Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gamida Cell Ltd. - Ordinary Shares (NQ:GMDA)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gamida Cell Ltd. - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference
From Gamida Cell Ltd.
Via Business Wire
News headline image
GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa
From Gamida Cell Ltd.
Via Business Wire
News headline image
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares
From Gamida Cell
Via Business Wire
News headline image
Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Announces Launch of Public Offering of Ordinary Shares
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors
From Gamida Cell
Via Business Wire
News headline image
Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201
From Gamida Cell
Via Business Wire
News headline image
Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference
From Gamida Cell Ltd.
Via Business Wire
News headline image
Gamida Cell Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
From Gamida Cell Ltd.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.